Skip to main content
Top
Published in: Diabetologia 7/2007

01-07-2007 | Article

Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet

Authors: M. Sörhede Winzell, C. L. Brand, N. Wierup, U. G. Sidelmann, F. Sundler, E. Nishimura, B. Ahrén

Published in: Diabetologia | Issue 7/2007

Login to get access

Abstract

Aims/hypothesis

Increased glucagon secretion predicts deterioration of glucose tolerance, and high glucagon levels contribute to hyperglycaemia in type 2 diabetes. Inhibition of glucagon action may therefore be a potential novel target to reduce hyperglycaemia. Here, we investigated whether chronic treatment with a glucagon receptor antagonist (GRA) improves islet dysfunction in female mice on a high-fat diet (HFD).

Materials and methods

After 8 weeks of HFD, mice were treated with a small molecule GRA (300 mg/kg, gavage once daily) for up to 30 days. Insulin secretion was studied after oral and intravenous administration of glucose and glucagon secretion after intravenous arginine. Islet morphology was examined and insulin secretion and glucose oxidation were measured in isolated islets.

Results

Fasting plasma glucose levels were reduced by GRA (6.0 ± 0.2 vs 7.4 ± 0.5 mmol/l; p = 0.017). The acute insulin response to intravenous glucose was augmented (1,300 ± 110 vs 790 ± 64 pmol/l; p < 0.001). The early insulin response to oral glucose was reduced in mice on HFD + GRA (1,890 ± 160 vs 3,040 ± 420 pmol/l; p = 0.012), but glucose excursions were improved. Intravenous arginine significantly increased the acute glucagon response (129 ± 12 vs 36 ± 6 ng/l in controls; p < 0.01), notably without affecting plasma glucose. GRA caused a modest increase in alpha cell mass, while beta cell mass was similar to that in mice on HFD + vehicle. Isolated islets displayed improved glucose-stimulated insulin secretion after GRA treatment (0.061 ± 0.007 vs 0.030 ± 0.004 pmol islet−1 h−1 at 16.7 mmol/l glucose; p < 0.001), without affecting islet glucose oxidation.

Conclusions/interpretation

Chronic glucagon receptor antagonism in HFD-fed mice improves islet sensitivity to glucose and increases insulin secretion, suggesting improvement of key defects underlying impaired glucose tolerance and type 2 diabetes.
Literature
1.
go back to reference Cherrington AD, Chiasson JL, Liljenquist JE, Lacy WW, Park CR (1978) Control of hepatic glucose output by glucagon and insulin in the intact dog. Biochem Soc Symp 43:31–45PubMed Cherrington AD, Chiasson JL, Liljenquist JE, Lacy WW, Park CR (1978) Control of hepatic glucose output by glucagon and insulin in the intact dog. Biochem Soc Symp 43:31–45PubMed
2.
go back to reference Jiang G, Zhang BB (2003) Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 284:E671–E678PubMed Jiang G, Zhang BB (2003) Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 284:E671–E678PubMed
3.
go back to reference Ikeda T, Hoshino T, Honda M et al (1989) Effect of glucagon on glucose output from bivascularly perfused rat liver. Exp Clin Endocrinol 94:383–386PubMed Ikeda T, Hoshino T, Honda M et al (1989) Effect of glucagon on glucose output from bivascularly perfused rat liver. Exp Clin Endocrinol 94:383–386PubMed
4.
go back to reference Beuers U, Jungermann K (1990) Relative contribution of glycogenolysis and gluconeogenesis to basal, glucagon- and nerve stimulation-dependent glucose output in the perfused liver from fed and fasted rats. Biochem Int 21:405–415PubMed Beuers U, Jungermann K (1990) Relative contribution of glycogenolysis and gluconeogenesis to basal, glucagon- and nerve stimulation-dependent glucose output in the perfused liver from fed and fasted rats. Biochem Int 21:405–415PubMed
5.
go back to reference Shah P, Basu A, Basu R, Rizza R (1999) Impact of lack of suppression of glucagon on glucose tolerance in humans. Am J Physiol 277:E283–E290PubMed Shah P, Basu A, Basu R, Rizza R (1999) Impact of lack of suppression of glucagon on glucose tolerance in humans. Am J Physiol 277:E283–E290PubMed
6.
go back to reference Sloop KW, Michael MD, Moyers JS (2005) Glucagon as a target for the treatment of type 2 diabetes. Expert Opin Ther Targets 9:593–600CrossRefPubMed Sloop KW, Michael MD, Moyers JS (2005) Glucagon as a target for the treatment of type 2 diabetes. Expert Opin Ther Targets 9:593–600CrossRefPubMed
7.
go back to reference Dobbs R, Sakurai H, Sasaki H et al (1975) Glucagon: role in the hyperglycemia of diabetes mellitus. Science 187:544–547CrossRefPubMed Dobbs R, Sakurai H, Sasaki H et al (1975) Glucagon: role in the hyperglycemia of diabetes mellitus. Science 187:544–547CrossRefPubMed
8.
go back to reference Unger RH, Orci L (1975) The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1:14–16CrossRefPubMed Unger RH, Orci L (1975) The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1:14–16CrossRefPubMed
9.
go back to reference Gerich JE, Lorenzi M, Karam JH, Schneider V, Forsham PH (1975) Abnormal pancreatic glucagon secretion and postprandial hyperglycemia in diabetes mellitus. JAMA 234:155–159CrossRef Gerich JE, Lorenzi M, Karam JH, Schneider V, Forsham PH (1975) Abnormal pancreatic glucagon secretion and postprandial hyperglycemia in diabetes mellitus. JAMA 234:155–159CrossRef
10.
go back to reference Unger RH (1978) Role of glucagon in the pathogenesis of diabetes: the status of the controversy. Metabolism 27:1691–1709CrossRefPubMed Unger RH (1978) Role of glucagon in the pathogenesis of diabetes: the status of the controversy. Metabolism 27:1691–1709CrossRefPubMed
11.
go back to reference Larsson H, Ahren B (2000) Glucose intolerance is predicted by low insulin secretion and high glucagon secretion: outcome of a prospective study in postmenopausal Caucasian women. Diabetologia 43:194–202CrossRefPubMed Larsson H, Ahren B (2000) Glucose intolerance is predicted by low insulin secretion and high glucagon secretion: outcome of a prospective study in postmenopausal Caucasian women. Diabetologia 43:194–202CrossRefPubMed
12.
go back to reference Muller WA, Faloona GR, Aguilar-Parada E, Unger RH (1970) Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 283:109–115PubMedCrossRef Muller WA, Faloona GR, Aguilar-Parada E, Unger RH (1970) Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 283:109–115PubMedCrossRef
13.
go back to reference Aronoff SL, Bennett PH, Unger RH (1977) Immunoreactive glucagon (IRG) responses to intravenous glucose in prediabetes and diabetes among Pima Indians and normal Caucasians. J Clin Endocrinol Metab 44:968–972PubMed Aronoff SL, Bennett PH, Unger RH (1977) Immunoreactive glucagon (IRG) responses to intravenous glucose in prediabetes and diabetes among Pima Indians and normal Caucasians. J Clin Endocrinol Metab 44:968–972PubMed
14.
go back to reference Ohneda A, Watanabe K, Horigome K, Sakai T, Kai Y, Oikawa S (1978) Abnormal response of pancreatic glucagon to glycemic changes in diabetes mellitus. J Clin Endocrinol Metab 46:504–510PubMedCrossRef Ohneda A, Watanabe K, Horigome K, Sakai T, Kai Y, Oikawa S (1978) Abnormal response of pancreatic glucagon to glycemic changes in diabetes mellitus. J Clin Endocrinol Metab 46:504–510PubMedCrossRef
15.
go back to reference Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB (1987) Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64:106–110PubMed Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB (1987) Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64:106–110PubMed
16.
go back to reference Baron AD, Schaeffer L, Shragg P, Kolterman OG (1987) Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 36:274–283CrossRefPubMed Baron AD, Schaeffer L, Shragg P, Kolterman OG (1987) Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 36:274–283CrossRefPubMed
17.
go back to reference Basu R, Chandramouli V, Dicke B, Landau B, Rizza R (2005) Obesity and type 2 diabetes impair insulin-induced suppression of glycogenolysis as well as gluconeogenesis. Diabetes 54:1942–1948CrossRefPubMed Basu R, Chandramouli V, Dicke B, Landau B, Rizza R (2005) Obesity and type 2 diabetes impair insulin-induced suppression of glycogenolysis as well as gluconeogenesis. Diabetes 54:1942–1948CrossRefPubMed
18.
go back to reference Brand CL, Jorgensen PN, Knigge U et al (1995) Role of glucagon in maintenance of euglycemia in fed and fasted rats. Am J Physiol 269:E469–E477PubMed Brand CL, Jorgensen PN, Knigge U et al (1995) Role of glucagon in maintenance of euglycemia in fed and fasted rats. Am J Physiol 269:E469–E477PubMed
19.
go back to reference Brand CL, Rolin B, Jorgensen PN, Svendsen I, Kristensen JS, Holst JJ (1994) Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats. Diabetologia 37:985–993PubMed Brand CL, Rolin B, Jorgensen PN, Svendsen I, Kristensen JS, Holst JJ (1994) Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats. Diabetologia 37:985–993PubMed
20.
go back to reference Brand CL, Jorgensen PN, Svendsen I, Holst JJ (1996) Evidence for a major role for glucagon in regulation of plasma glucose in conscious, nondiabetic, and alloxan-induced diabetic rabbits. Diabetes 45:1076–1083CrossRefPubMed Brand CL, Jorgensen PN, Svendsen I, Holst JJ (1996) Evidence for a major role for glucagon in regulation of plasma glucose in conscious, nondiabetic, and alloxan-induced diabetic rabbits. Diabetes 45:1076–1083CrossRefPubMed
21.
go back to reference Johnson DG, Goebel CU, Hruby VJ, Bregman MD, Trivedi D (1982) Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist. Science 215:1115–1116CrossRefPubMed Johnson DG, Goebel CU, Hruby VJ, Bregman MD, Trivedi D (1982) Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist. Science 215:1115–1116CrossRefPubMed
22.
go back to reference Van Tine BA, Azizeh BY, Trivedi D et al (1996) Low level cyclic adenosine 3′,5′-monophosphate accumulation analysis of [des-His1, des-Phe6, Glu9] glucagon-NH2 identifies glucagon antagonists from weak partial agonists/antagonists. Endocrinology 137:3316–3322CrossRefPubMed Van Tine BA, Azizeh BY, Trivedi D et al (1996) Low level cyclic adenosine 3′,5′-monophosphate accumulation analysis of [des-His1, des-Phe6, Glu9] glucagon-NH2 identifies glucagon antagonists from weak partial agonists/antagonists. Endocrinology 137:3316–3322CrossRefPubMed
23.
go back to reference Ling A, Plewe M, Gonzalez J et al (2002) Human glucagon receptor antagonists based on alkylidene hydrazides. Bioorg Med Chem Lett 12:663–666CrossRefPubMed Ling A, Plewe M, Gonzalez J et al (2002) Human glucagon receptor antagonists based on alkylidene hydrazides. Bioorg Med Chem Lett 12:663–666CrossRefPubMed
24.
go back to reference Shen DM, Zhang F, Brady EJ et al (2005) Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists. Bioorg Med Chem Lett 15:4564–4569CrossRefPubMed Shen DM, Zhang F, Brady EJ et al (2005) Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists. Bioorg Med Chem Lett 15:4564–4569CrossRefPubMed
25.
go back to reference Qureshi SA, Rios Candelore M, Xie D et al (2004) A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. Diabetes 53:3267–3273CrossRefPubMed Qureshi SA, Rios Candelore M, Xie D et al (2004) A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. Diabetes 53:3267–3273CrossRefPubMed
26.
go back to reference Petersen KF, Sullivan JT (2001) Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 44:2018–2024CrossRefPubMed Petersen KF, Sullivan JT (2001) Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 44:2018–2024CrossRefPubMed
27.
go back to reference Liang Y, Osborne MC, Monia BP et al (2004) Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes 53:410–417CrossRefPubMed Liang Y, Osborne MC, Monia BP et al (2004) Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes 53:410–417CrossRefPubMed
28.
go back to reference Sloop KW, Cao JX, Siesky AM et al (2004) Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest 113:1571–1581CrossRefPubMed Sloop KW, Cao JX, Siesky AM et al (2004) Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest 113:1571–1581CrossRefPubMed
29.
go back to reference Gelling RW, Du XQ, Dichmann DS et al (2003) Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A 100:1438–1443CrossRefPubMed Gelling RW, Du XQ, Dichmann DS et al (2003) Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A 100:1438–1443CrossRefPubMed
30.
go back to reference Parker JC, Andrews KM, Allen MR, Stock JL, McNeish JD (2002) Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem Biophys Res Commun 290:839–843CrossRefPubMed Parker JC, Andrews KM, Allen MR, Stock JL, McNeish JD (2002) Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem Biophys Res Commun 290:839–843CrossRefPubMed
31.
go back to reference Sorensen H, Winzell MS, Brand CL et al (2006) Glucagon receptor knockout mice display increased insulin sensitivity and impaired beta-cell function. Diabetes 55:3463–3469CrossRefPubMed Sorensen H, Winzell MS, Brand CL et al (2006) Glucagon receptor knockout mice display increased insulin sensitivity and impaired beta-cell function. Diabetes 55:3463–3469CrossRefPubMed
32.
go back to reference Bergman RN, Phillips LS, Cobelli C (1981) Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 68:1456–1467PubMedCrossRef Bergman RN, Phillips LS, Cobelli C (1981) Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 68:1456–1467PubMedCrossRef
33.
go back to reference Kahn SE, Prigeon RL, McCulloch DK et al (1994) The contribution of insulin-dependent and insulin-independent glucose uptake to intravenous glucose tolerance in healthy human subjects. Diabetes 43:587–592CrossRefPubMed Kahn SE, Prigeon RL, McCulloch DK et al (1994) The contribution of insulin-dependent and insulin-independent glucose uptake to intravenous glucose tolerance in healthy human subjects. Diabetes 43:587–592CrossRefPubMed
34.
go back to reference Larsson H, Ahren B (1996) Failure to adequately adapt reduced insulin sensitivity with increased insulin secretion in women with impaired glucose tolerance. Diabetologia 39:1099–1107PubMed Larsson H, Ahren B (1996) Failure to adequately adapt reduced insulin sensitivity with increased insulin secretion in women with impaired glucose tolerance. Diabetologia 39:1099–1107PubMed
35.
go back to reference Porte D, Jr, Kahn SE (2001) Beta-cell dysfunction and failure in type 2 diabetes: potential mechanisms. Diabetes 50(Suppl 1):S160–S163CrossRefPubMed Porte D, Jr, Kahn SE (2001) Beta-cell dysfunction and failure in type 2 diabetes: potential mechanisms. Diabetes 50(Suppl 1):S160–S163CrossRefPubMed
36.
go back to reference Huypens P, Ling Z, Pipeleers D, Schuit F (2000) Glucagon receptors on human islet cells contribute to glucose competence of insulin release. Diabetologia 43:1012–1019CrossRefPubMed Huypens P, Ling Z, Pipeleers D, Schuit F (2000) Glucagon receptors on human islet cells contribute to glucose competence of insulin release. Diabetologia 43:1012–1019CrossRefPubMed
37.
go back to reference Pacini G, Thomaseth K, Ahren B (2001) Contribution to glucose tolerance of insulin-independent vs insulin-dependent mechanisms in mice. Am J Physiol Endocrinol Metab 281:E693–E703PubMed Pacini G, Thomaseth K, Ahren B (2001) Contribution to glucose tolerance of insulin-independent vs insulin-dependent mechanisms in mice. Am J Physiol Endocrinol Metab 281:E693–E703PubMed
38.
go back to reference Winzell MS, Ahren B (2004) The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 53(Suppl 3):S215–S219CrossRefPubMed Winzell MS, Ahren B (2004) The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 53(Suppl 3):S215–S219CrossRefPubMed
39.
go back to reference Ahren B, Simonsson E, Scheurink AJ, Mulder H, Myrsen U, Sundler F (1997) Dissociated insulinotropic sensitivity to glucose and carbachol in high-fat diet-induced insulin resistance in C57BL/6J mice. Metabolism 46:97–106CrossRefPubMed Ahren B, Simonsson E, Scheurink AJ, Mulder H, Myrsen U, Sundler F (1997) Dissociated insulinotropic sensitivity to glucose and carbachol in high-fat diet-induced insulin resistance in C57BL/6J mice. Metabolism 46:97–106CrossRefPubMed
40.
go back to reference Rivera N, Everett CA, Edgerton DS et al (2007) A novel glucagon receptor antagonist, NNC 25-0926, blunts hepatic glucose production in the conscious dog. J Pharmacol Exp Ther DOI 10.1124/jept.106.115717 Rivera N, Everett CA, Edgerton DS et al (2007) A novel glucagon receptor antagonist, NNC 25-0926, blunts hepatic glucose production in the conscious dog. J Pharmacol Exp Ther DOI 10.​1124/​jept.​106.​115717
41.
go back to reference Wierup N, Kuhar M, Nilsson BO, Mulder H, Ekblad E, Sundler F (2004) Cocaine- and amphetamine-regulated transcript (CART) is expressed in several islet cell types during rat development. J Histochem Cytochem 52:169–177PubMed Wierup N, Kuhar M, Nilsson BO, Mulder H, Ekblad E, Sundler F (2004) Cocaine- and amphetamine-regulated transcript (CART) is expressed in several islet cell types during rat development. J Histochem Cytochem 52:169–177PubMed
42.
go back to reference Harndahl L, Wierup N, Enerback S et al (2004) Beta-cell-targeted overexpression of phosphodiesterase 3B in mice causes impaired insulin secretion, glucose intolerance, and deranged islet morphology. J Biol Chem 279:15214–15222CrossRefPubMed Harndahl L, Wierup N, Enerback S et al (2004) Beta-cell-targeted overexpression of phosphodiesterase 3B in mice causes impaired insulin secretion, glucose intolerance, and deranged islet morphology. J Biol Chem 279:15214–15222CrossRefPubMed
43.
go back to reference Rouille Y, Bianchi M, Irminger JC, Halban PA (1997) Role of the prohormone convertase PC2 in the processing of proglucagon to glucagon. FEBS Lett 413:119–123CrossRefPubMed Rouille Y, Bianchi M, Irminger JC, Halban PA (1997) Role of the prohormone convertase PC2 in the processing of proglucagon to glucagon. FEBS Lett 413:119–123CrossRefPubMed
44.
go back to reference Rouille Y, Kantengwa S, Irminger JC, Halban PA (1997) Role of the prohormone convertase PC3 in the processing of proglucagon to glucagon-like peptide 1. J Biol Chem 272:32810–32816CrossRefPubMed Rouille Y, Kantengwa S, Irminger JC, Halban PA (1997) Role of the prohormone convertase PC3 in the processing of proglucagon to glucagon-like peptide 1. J Biol Chem 272:32810–32816CrossRefPubMed
45.
go back to reference Hui H, Dotta F, Di Mario U, Perfetti R (2004) Role of caspases in the regulation of apoptotic pancreatic islet beta-cells death. J Cell Physiol 200:177–200CrossRefPubMed Hui H, Dotta F, Di Mario U, Perfetti R (2004) Role of caspases in the regulation of apoptotic pancreatic islet beta-cells death. J Cell Physiol 200:177–200CrossRefPubMed
46.
go back to reference Dallas-Yang Q, Shen X, Strowski M et al (2004) Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists. Eur J Pharmacol 501:225–234CrossRefPubMed Dallas-Yang Q, Shen X, Strowski M et al (2004) Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists. Eur J Pharmacol 501:225–234CrossRefPubMed
Metadata
Title
Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet
Authors
M. Sörhede Winzell
C. L. Brand
N. Wierup
U. G. Sidelmann
F. Sundler
E. Nishimura
B. Ahrén
Publication date
01-07-2007
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 7/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-007-0675-3

Other articles of this Issue 7/2007

Diabetologia 7/2007 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.